FDA: Simplified Registration for U.S. Sites and Greater Complexity for Non-U.S. Sites

The U.S. Food and Drug Administration (FDA) has published a proposal to modernize the registration of drug manufacturers. On the one hand, the proposed rule is intended to simplify the registration of multiple sites operating under a single corporate umbrella in the United States. On the other hand, it aims to improve transparency regarding foreign manufacturers that produce drugs, active pharmaceutical ingredients, or drug components for the U.S. market.

Registration as a Single Establishment

The proposal focuses on the so-called "hub-and-spoke model". Under this model, a central site-the "hub"-provides overarching quality oversight for several equivalent manufacturing establishments operated at different locations.

Under the current U.S. regulations, the individual sites within such a network generally have to be registered separately, resulting in a corresponding administrative burden. The proposed rule would allow qualifying manufacturers to register multiple sites as a single establishment. Changes within the network, for example addition, relocation, or removal of individual manufacturing establishments could be handled through a simplified update process.

Greater Complexity for Foreign Manufacturers

Another key aspect concerns certain foreign facilities. According to the FDA, not all foreign establishments that manufacture drugs, drug components, or active pharmaceutical ingredients and initially supply them to other foreign companies are currently registered. Such facilities may form part of a supply chain for drugs that are subsequently imported into the United States. If they are not registered, the FDA has only limited visibility into the upstream stages of the supply chain.

The proposed rule is therefore intended to clarify that these establishments must be registered with the FDA, provided they fall within the scope of the statutory requirements. According to the agency, this would improve the traceability of active ingredients and other starting materials and strengthen its ability to identify and respond to potential problems at an early stage.

Significance for the Pharmaceutical Industry

If finalised in its proposed form, the rule could reduce the registration burden and simplify update processes for companies operating distributed manufacturing establishments in the United States.

For companies with international supply chains, however, the requirements would become more complex. They will need to assess whether all upstream manufacturing sites are fully covered by the applicable registration requirements.

At this stage, the rule is only a proposal. The planned changes are therefore not yet legally binding. Companies that manufacture drugs or active pharmaceutical ingredients in the United States, or that supply the U.S. market through international manufacturing networks, should monitor further developments and review their existing registration and supply-chain structures at an early stage.

The FDA's press release is available under the title: "FDA Proposes Rule to Modernize Drug Manufacturing Registration."